MOTS-c: A Promising New Player in Ovarian Cancer Treatment
Published: May 16, 2026 | Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024) | Category: MOTS-c
Overview
A recent study published in Advanced Science has uncovered a potential new therapeutic target for ovarian cancer (OC): the mitochondrial-derived peptide MOTS-c. This research highlights how MOTS-c can inhibit OC cell proliferation and migration by targeting specific cellular pathways, suggesting its role as a promising candidate for future clinical interventions.
Study Background
Mitochondria are not only energy-producing organelles but also play critical roles in signaling and maintaining cellular homeostasis through the release of various peptides. One such peptide is MOTS-c (mitochondrial open reading frame of the 12S rRNA C), which has been previously implicated in metabolic regulation and aging processes. However, its role in cancer progression was largely unknown until this recent study.
What the Research Found
The research team discovered that MOTS-c levels are significantly reduced in both serum and tumor tissues from OC patients compared to healthy controls. This reduction correlates with poorer patient prognosis. When exogenous MOTS-c is introduced into OC cells, it inhibits their proliferation, migration, and invasion capabilities while inducing cell cycle arrest and apoptosis.
Mechanistically, the study identified that MOTS-c interacts directly with LARS1 (Leucyl-tRNA synthetase 1), a protein known to play an oncogenic role in OC. By promoting LARS1 ubiquitination and subsequent proteasomal degradation, MOTS-c effectively suppresses its oncogenic function. Additionally, the study revealed that USP7 (Ubiquitin Specific Peptidase 7) acts as a deubiquitinase for LARS1, thereby stabilizing it. However, MOTS-c competes with USP7 to bind LARS1, thus attenuating this stabilization process.
What This Means for Peptide Users
While the findings are promising, it's important to note that this study primarily focuses on in vitro and preclinical models of OC. For peptide users interested in therapeutic applications, these results suggest a potential future role for MOTS-c or similar peptides in targeted cancer therapies. However, further research is necessary before clinical application can be considered.
Limitations and Caveats
The study lacks detailed information regarding the sample size used for human subjects, which limits its statistical power and generalizability to broader populations. Additionally, while preclinical models demonstrated a marked anti-tumor effect of MOTS-c without systemic toxicity, these findings need validation in larger animal studies and eventually in human clinical trials.
How This Compares to Previous Research
Previous research has highlighted the role of mitochondrial peptides like MOTS-c in metabolic regulation but did not specifically address their involvement in cancer progression. The current study builds upon this foundation by elucidating a novel mechanism through which MOTS-c can suppress OC growth, thereby bridging the gap between mitochondrial signaling and oncogenesis.
Our Analysis
The research provides compelling evidence for the potential of MOTS-c as a therapeutic agent against ovarian cancer. However, given its preliminary nature and focus on preclinical models, it is crucial to approach these findings with caution until further validation in human subjects is achieved. The study's detailed mechanistic insights offer valuable groundwork for future investigations into mitochondrial peptides' roles in cancer biology.
Key Takeaways
- MOTS-c levels are reduced in ovarian cancer patients, correlating with poorer prognosis.
- Exogenous MOTS-c inhibits OC cell proliferation and migration by targeting LARS1 via USP7 interaction.
- The study highlights the potential of MOTS-c as a therapeutic target but requires further validation in clinical settings.
Original Source
Citation: Yin Yadong, Li Yujie, Ma Boyi et al. (2024). Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). DOI: 10.1002/advs.202405620
Access: https://pubmed.ncbi.nlm.nih.gov/39321430/
---
This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.